Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006472 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2 study, sponsored by Prilenia.
- Completed
- Registry status
- Phase 2
- Development phase
- 408
- Enrollment target
NCT02006472: Completed Phase 2 study, sponsored by Prilenia.
NCT02006472 is a Phase 2 study that has completed, run by Prilenia. The registered enrollment target is 408 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (207% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02006472, a Phase 2 study, has completed, sponsored by Prilenia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 408 participants
- Enrollment target
Study Summary
This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).
Primary Outcome
TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.
Interventions
- OTHER Placebo
- DRUG Pridopidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2014-02-28 |
| Est. Completion | 2016-07-07 |
| Phase | Phase 2 |
What the finished NCT02006472 record still lists
NCT02006472 is an interventional study that assigns participants to a tested intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (207% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02006472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02006472 about?
NCT02006472 is a clinical study titled "A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease". This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).
What is the current status of trial NCT02006472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 408 participants. The study started on 2014-02-28. Estimated completion is 2016-07-07.
What interventions are being tested in trial NCT02006472?
The interventions under investigation include: Placebo (OTHER), Pridopidine (DRUG).
Who is sponsoring clinical trial NCT02006472?
This trial is sponsored by Prilenia, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02006472's enrollment target sits among peer trials
408 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI